The use of transgenic mice to generate high affinity p53 specific cytolytic T cells

Journal of Surgical Research

Volumn 69, Issue 2, 1997, Pages 337-343

  Yu, Zhiwei ^a   Liu, Xiping ^a   McCarty, Todd M ^a   Diamond, Don J ^a   Ellenhorn, Joshua D I ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; PROTEIN P53; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TRANSGENIC MOUSE;

EID: 0031147763     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5058     Document Type: Conference Paper

References (46)

1. 1. Rosenberg, S. A. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J. Sci. Am. 1: 90, 1995.
2. 2. Houghton, A. N. On course for a cancer vaccine. Lancet 345: 1384, 1995.
3. 3. Koller, B. H., and Orr, H. T. Cloning and complete sequence of an HLA-A2 gene: analysis of two HLA-A alleles at the nucleotide level. J. Immunol. 134: 2727, 1985.
4. 4. King, D. S., Fields, C. G., and Fields, G. B. A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int. J. Pept. Protein Res. 36: 255, 1990.
5. 5. Le, A., Bernhard, E. J., Holterman, M. J., Strub, S., Parham, P., Lacy, E., and Engelhard, V. H. Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element. J. Immunol. 142: 1366, 1989.
6. 6. Bernhard, E. J., Le, A. X., Barbosa, J. A., Lacy, E., and Engelhard, V. H. Cytotoxic T lymphocytes from HLA-A2 transgenic mice specific for HLA-A2 expressed on human cells. J. Exp. Med. 168: 1157, 1988.
7. 7. Tiercy, J. M., Djavad, N., Rufer, N., Speiser, D. E., Jeannet, M., and Roosnek, E. Oligotyping of HLA-A2, -A3, and -B44 subtypes. Detection of subtype incompatibilities between patients and their serologically matched unrelated bone marrow donors. Hum. Immunol. 41: 207, 1994.
8. 8. Fernandez-Vina, M. A., Falco, M., Sun, Y., and Stastny, P. DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28. Hum. Immunol. 33: 163, 1992.
9. 9. Parham, P., and Brodsky, F. M. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum. Immunol. 3: 277, 1981.
10. 10. Parham, P., Kipps, T. J., Ward, F. E., and Herzenberg, L. A. Isolation of heavy chain class switch variants of a monoclonal anti-DC1 hybridoma cell line: Effective conversion of noncytotoxic IgG1 antibodies to cytotoxic IgG2 antibodies. Hum. Immunol. 8: 141, 1983.
11. 11. Noguchi, Y., Chen, Y. T., and Old, L. J. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. USA 91: 3171, 1994.
12. 12. Storkus, W. J., Zeh, H. J., Maeurer, M. J., Salter, R. D., and Lotze, M. T. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J. Immunol. 151: 3719, 1993.
13. 13. Wentworth, P. A., Celis, E., Crimi, C., Stitely, S., Hale, L., Tsai, V., Serra, H. M., Del Guercio, M. F., Livingston, B., and Alazard, D. In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. Mol. Immunol. 32: 603, 1995.
14. 14. D'Amaro, J., Houbiers, J. G., Drijfhout, J. W., Brandt, R. M., Schipper, R., Bavinck, J. N., Melief, C. J., and Kast, W. M. A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. Hum. Immunol. 43: 13, 1995.
15. 15. Ropke, M., Regner, M., and Claesson, M. H. T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors. Scand. J. Immunol. 42: 98, 1995.
16. 16. Stukart, M. J., Boes, J., and Melief, C. J. Mutations in H-2Kb influence the specificity of alloreactive effector cells included in the repertoire of H-2Db-restricted cytotoxic T lymphocytes against Moloney leukemia virus. Immunogenetics 17: 427, 1983.
17. 17. Nijman, H. W., Houbiers, J. G., van der Burg, S. H., Vierboom, M. P., Kenemans, P., Kast, W. M., and Melief, C. J. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: Relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J. Immunother. 14: 121, 1993.
18. 18. Ropke, M., Hald, J., Guldberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Svejgaard, A., Van der Burg, S., Nijman, H. W., Melief, C. J., and Claesson, M. H. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA 93: 14704, 1996.
19. 19. Engelhard, V. H., Lacy, E., and Ridge, J. P. Influenza A-specific, HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein. J. Immunol. 8293: 11552, 1991.
20. 20. Shirai, M., Arichi, T., Nishioka, M., Nomura, T., Ikeda, K., Kawanishi, K., Engelhard, V. H., Feinstone, S. M., and Berzofsky, J. A. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol 154: 2733, 1995.
21. 21. Vitiello, A., Marchesini, D., Furze, J., Sherman, L. A., and Chesnut, R. W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173: 1007, 1991.
22. 22. Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H. M., Kubo, R. T., and Sette, A. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1: 751, 1994.
23. 23. Storkus, W. J., Zeh, H. J., 3d, Salter, R. D., and Lotze, M. T. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J. Immunother. 14: 94, 1993.
24. 24. Kovach, J. S., Hartmann, A., Blaszyk, H., Cunningham, J., Schaid, D., and Sommer, S. S. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA 93: 1093, 1996.
25. 25. Finlay, C. A., Hinds, P. W., and Levine, A. J. The p53 protooncogene can act as a suppressor of transformation. Cell 57: 1083, 1989.
26. 26. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., and Oren, M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA 86: 8763, 1989.
27. 27. Oldstone, M. B., Tishon, A., Geckeler, R., Lewicki, H., and Whitton, J. L. A common antiviral cytotoxic T-lymphocyte epitope for diverse major histocompatibility complex haplotypes: Implications for vaccination. Proc. Natl. Acad. Sci. USA 89: 2752, 1992.
28. 28. Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., and Levine, A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell Biol. 8: 531, 1988.
29. 29. Zambetti, G. P., and Levine, A. J. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 7: 855, 1993.
30. 30. Reich, N. C., and Levine, A. J. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature 308: 199, 1984.
31. 31. Tilkin, A. F., Lubin, R., Soussi, T., Lazar, V., Janin, N., Mathieu, M. C., Lefrere, I., Carlu, C., Roy, M., and Kayibanda, M. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur. J. Immunol. 25: 1765, 1995.
32. 32. Roth, J., Dittmer, D., Rea, D., Tartaglia, J., Paoletti, E., and Levine, A. J. p53 as a target for vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor challenge. Proc. Natl. Acad. Sci. USA 93: 4781, 1996.
33. 33. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., DeCesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., and DeLeo, A. B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183: 1357, 1996.
34. 34. Wiedenfeld, E. A., Fernandez-Vina, M., Berzofsky, J. A., and Carbone, D. P. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. Cancer Res. 54: 1175, 1994.
35. 35. Vierboom, M. P., Nijman, H. W., Offringa, R., van der Voort, E. I., van Hall, T., Kenemans, P., Kast, W. M., and Melief, C. J. Tumor eradication by wild type p53 specific cytotoxic T lymphocytes. Keystone Symposia: Cellular Immunology and the Immunotherapy of Cancer - III:31, 1997. (Abstract)
36. 36. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neuderived peptide. Proc. Natl. Acad. Sci. USA 92: 432, 1995.
37. 37. Yanuck, M., Carbone, D. P., Pendleton, C. D., Tsukui, T., Winter, S. F., Minna, J. D., and Berzofsky, J. A. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res. 53: 3257, 1993.
38. 38. Houbiers, J. G., Nijman, H. W., van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde, C. J., Brand, A., Momburg, F., Kast, W. M., and Melief, C. J. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23: 2072, 1993.
39. 39. Disis, M. L., Smith, J. W., Murphy, A. E., Chen, W., and Cheever, M. A. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res. 54: 1071, 1995.
40. 40. Mandelbolm, O., Berke, G., Fridkin, M., Feldman, M., Eisenstein, M., and Eisenbach, L. CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369: 67, 1994.
41. 41. Nijman, H. W., van der Burg, S. H., Vierboom, M. P., Houbiers, J. G., Kast, W. M., and Melief, C. J. p53, a potential target for tumor-directed T cells. Immunol. Lett. 40: 171, 1994.
42. 42. Goverman, J., Gomez, S. M., Segesman, K. D., Hunkapiller, T., Laug, W. E., and Hood, L. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: Implications for T cell receptor complex formation and activation. Cell 60: 929, 1990.
43. 43. Romeo, C., Kolanus, W., Amiot, M., and Seed, B. Activation of immune system effector function by T-cell or Fc receptor intracellular domains. Cold Spring Harb. Symp. Quant. Biol. 57: 117, 1992.
44. 44. Kolanus, W., Romeo, C., and Seed, B. Lineage-independent activation of immune system effector function by myeloid Fc receptors. EMBO J. 11: 4861, 1992.
45. 45. Hwu, X., Shafer, G. E., Treisman, J., Schindler, D. G., Gross, G., Cowherd, R., Rosenberg, S. A., and Eshhar, Z. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J. Exp. Med. 178: 361, 1993.
46. 46. Eshhar, Z., Waks, T., Gross, G., and Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90: 720, 1993.